Utilizing genetic manipulation to combat infectious ailments
A groundbreaking research project, named 'AGEnTS', is underway at Friedrich-Alexander University Erlangen-Nürnberg (FAU), with the aim to combat drug-resistant herpes viruses using genetically modified immune cells. Dr. Kilian Schober, the head of the project from the Institute of Microbiology - Clinical Microbiology, Immunology and Hygiene at Universitätsklinikum Erlangen, leads this innovative endeavour.
The 'AGEnTS' project employs innovative genetic engineering methods to modify T-cells, a specific type of immune cell. The use of gene scissors simplifies the process, making it more accessible and potentially reducing the cost of treatment. This modification process also eliminates the need for tailoring T-cells specifically for each individual patient.
The ultimate goal of the 'AGEnTS' project is to strengthen the immune system of individuals with drug-resistant herpes viruses. The modified T-cells, designed to remain similar to natural cells, are intended for transfer to individuals with potentially fatal infections caused by these drug-resistant viruses.
Dr. Schober's team hopes that the physiologically modified cells will help combat herpes viruses that have become resistant to medication. The long-term goal is to use this treatment method for other infectious diseases with drug-resistant pathogens. This could potentially open up a new avenue for treating diseases notoriously difficult to treat.
The Federal Ministry of Education and Research is providing 2,162,188 euros in funding for the 'AGEnTS' research project from 2021 to 2026. Although the exact name of the other researcher involved in the project at FAU is not explicitly mentioned, their collaboration is crucial in achieving the project's objectives.
The 'AGEnTS' project is focused on combating drug-resistant pathogens using genetically modified immune cells, beyond just herpes viruses. This could potentially revolutionise the treatment of various infectious diseases, making T-cell treatment more accessible to a wider range of patients.
